id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S5927 R15095 |
Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.99 [0.46;2.16] C excluded (control group) |
27/465 9/154 | 36 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5910 R14893 |
Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.33 [0.90;1.97] excluded (control group) |
27/465 27,939/689,482 | 27,966 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5918 R14989 |
Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.33 [0.83;2.12] | 27/465 69/1,708 | 96 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 1 studies | 1.33 [0.83;2.13] | 96 | 465 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 5927, 5910